Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 1996 Oct;23(10):1729-33.

Anti-PM/Scl autoantibodies in patients without clinical polymyositis or scleroderma

W Schnitz  1 , E Taylor-Albert, I N Targoff, M Reichlin, R H Scofield
Affiliations
  • PMID: 8895149
Case Reports

Anti-PM/Scl autoantibodies in patients without clinical polymyositis or scleroderma

W Schnitz et al. J Rheumatol. 1996 Oct.

Abstract

Objective: To characterize patients with anti-PM/Scl but no definite myositis-scleroderma (PM/SSc) overlap or either polymyositis/dermatomyositis (PM/DM) or systemic sclerosis (SSc) alone.

Methods: Review of all patients with anti-PM/Scl identified at a reference serologic clinical laboratory.

Results: We identified 5 patients with anti-PM/Scl not considered to have either PM, SSc, or PM/SSc. One had primary Sjögren's syndrome but the other 4 had some feature(s) of illness consistent with PM/DM or SSc, such as hypertensive crisis or interstitial lung disease. These 5 patients represented 10% of the total number of patients with anti-PM/Scl identified in our clinical laboratory.

Conclusion: Anti-PM/Scl may be a marker for atypical or subclinical presentations of the usually associated disease, or this autoantibody may precede expression of the underlying disease. The antibody may also be present in patients who never express PM, SSc, or PM/SSc. Anti-PM/Scl without the usually described illnesses is not uncommon in our series of 55 patients with anti-PM/Scl.

PubMed Disclaimer

Publication types

Substances